InflaRx Announces Izicopan Does Not Inhibit CYP3A4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy IFRX?
InflaRx announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions and liver toxicity. These results further support izicopan's potential as a differentiated, oral C5a receptor inhibitor. To build upon previous CYP interaction data for izicopan, which showed only marginal inhibition of CYP3A4 in a time-dependent inhibition IC50 shift assay, InflaRx conducted a mechanistically informative Ki-based TDI study. While TDI shift assays serve as rapid screening tools to identify potential time-dependent inhibition, Ki/Kinact studies provide a more definitive and quantitative assessment, enabling a reliable determination of the presence or absence of time-dependent inhibition. The Ki-based TDI study confirms that izicopan does not inhibit CYP3A4 and exhibits no time-dependent inhibition up to the highest tested concentration, supporting a low risk of clinically relevant DDIs. Using two probe substrates, midazolam and testosterone, no evidence of CYP3A4 time-dependent inhibition was observed, providing mechanistic confirmation of izicopan's favorable pharmacological profile. This feature is particularly important, as time-dependent CYP3A4 inhibition can result in DDIs, hepatotoxicity, or reduced metabolism of concomitant medications such as corticosteroids.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IFRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IFRX
Wall Street analysts forecast IFRX stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 1.590
Low
6.00
Averages
12.67
High
24.00
Current: 1.590
Low
6.00
Averages
12.67
High
24.00
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InflaRx's Izicopan Shows No Time-Dependent CYP3A4 Inhibition
- Reduced Drug Interaction Risk: InflaRx's izicopan demonstrates no time-dependent inhibition of CYP3A4 even at the highest concentration of 100 µM in in vitro studies, indicating a lower risk of drug-drug interactions and liver toxicity in clinical applications.
- Mechanistic Study Support: The Ki/Kinact study confirms that izicopan does not inhibit CYP3A4 (IC₅₀ > 100 µM), further validating its safety in drug metabolism and enhancing its potential as a best-in-class oral C5aR inhibitor.
- Positive Clinical Data: In clinical trials involving patients with hidradenitis suppurativa, izicopan significantly reduced abscesses and nodules over four weeks, demonstrating biologic-like efficacy and further solidifying its market competitiveness.
- Scientific Leadership: Prof. Renfeng Guo, Chief Scientific Officer, emphasized that izicopan's unique pharmacological profile and favorable metabolic stability provide significant clinical application potential across various inflammatory diseases, potentially offering safer treatment options for patients.
See More
InflaRx to Participate in Biotech Innovation Symposium
- Investor Meeting Schedule: InflaRx N.V. will participate in the Raymond James Biotech Innovation Symposium on April 14, 2026, in New York, planning one-on-one investor meetings to enhance engagement and transparency with investors.
- Innovative Drug Development: InflaRx's lead program, izicopan (INF904), is an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and 2a clinical studies, potentially offering new treatment options for various inflammatory diseases.
- Anti-Inflammatory Therapy Potential: The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated disease-modifying activity and tolerability in multiple clinical studies, indicating its potential in treating inflammatory diseases.
- Global Business Presence: Founded in 2007, InflaRx has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, showcasing its capability for global business expansion and market penetration.
See More
InflaRx Scheduled to Announce FY Earnings Results
- Earnings Announcement Date: InflaRx (IFRX) is set to announce its FY earnings results on March 19 before market open, drawing attention to its performance and future outlook.
- Expected Financial Data: The consensus EPS estimate stands at -$0.17, reflecting a 78.2% year-over-year increase, while the revenue estimate is $0.09 million, indicating a 47.1% year-over-year decline, highlighting challenges the company faces.
- Historical Performance Review: Over the past year, InflaRx has not met EPS estimates 0% of the time and has only met revenue estimates 25% of the time, indicating volatility in profitability and revenue growth.
- Market Reaction: Investors will closely monitor the upcoming earnings report to assess InflaRx's financial health and its competitiveness in the biopharmaceutical sector.
See More
InflaRx Receives Nasdaq Non-Compliance Notice
- Nasdaq Non-Compliance Notice: InflaRx N.V. received a notice from Nasdaq indicating that its stock price has closed below the $1.00 minimum bid requirement for continued listing over the past 30 consecutive business days, potentially impacting the company's financing capabilities.
- Compliance Timeline and Transfer Options: The company has a 180-day period until September 7, 2026, to regain compliance; if unsuccessful, it may apply to transfer its listing to the Nasdaq Capital Market, gaining an additional 180 days, demonstrating the company's strategic response to market regulations.
- Clinical Program Developments: InflaRx's lead program, Izicopan, is under development for inflammatory diseases and has shown therapeutic potential, with plans to discuss future development paths with the FDA, likely in collaboration with a partner, enhancing its competitive position in the market.
- Financial Performance and Stock Volatility: IFRX shares have traded between $0.71 and $1.94 over the past year, closing at $0.94, down 3.56%, reflecting market caution regarding the company's future prospects.
See More
InflaRx Receives Nasdaq Warning for Non-Compliance
- Nasdaq Warning: InflaRx (IFRX) received a compliance warning from Nasdaq after its shares closed below the $1 minimum bid price for 30 consecutive trading days, indicating significant market pressure and potential financial distress for the company.
- Compliance Deadline: The company has been granted a 180-day grace period until September 7, 2026, to regain compliance with the minimum bid price requirement, providing a short-term opportunity for price recovery.
- Potential Transfer: InflaRx indicated it may apply to transfer its listing to the Nasdaq Capital Market, which could grant an additional 180 days until March 8, 2027, to regain compliance, showcasing the company's flexibility in addressing its challenges.
- Stock Price Decline: Following the announcement, InflaRx shares fell by 3.56%, reflecting market concerns about the company's future prospects, which may also impact investor confidence and its ability to raise capital.
See More
InflaRx to Participate in Global Healthcare Conference
- Conference Participation: InflaRx N.V. will participate in the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, with a fireside chat scheduled for March 9 at 9:20 AM, showcasing its latest advancements in anti-inflammatory therapeutics.
- Investor Meetings: On the same day, InflaRx will conduct one-on-one investor meetings aimed at strengthening connections with potential investors and enhancing the company's visibility in the capital markets.
- Technological Innovation: InflaRx focuses on developing anti-inflammatory therapies targeting the complement system, with its lead product izicopan demonstrating promising pharmacokinetic and pharmacodynamic characteristics in clinical studies, indicating potential for treating various inflammatory diseases.
- Company Background: Founded in 2007, InflaRx has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, and is dedicated to developing specific inhibitors of C5a and C5aR to address challenges in multiple inflammatory diseases.
See More
InflaRx's Izicopan Shows No Time-Dependent CYP3A4 Inhibition
- Reduced Drug Interaction Risk: InflaRx's izicopan demonstrates no time-dependent inhibition of CYP3A4 even at the highest concentration of 100 µM in in vitro studies, indicating a lower risk of drug-drug interactions and liver toxicity in clinical applications.
- Mechanistic Study Support: The Ki/Kinact study confirms that izicopan does not inhibit CYP3A4 (IC₅₀ > 100 µM), further validating its safety in drug metabolism and enhancing its potential as a best-in-class oral C5aR inhibitor.
- Positive Clinical Data: In clinical trials involving patients with hidradenitis suppurativa, izicopan significantly reduced abscesses and nodules over four weeks, demonstrating biologic-like efficacy and further solidifying its market competitiveness.
- Scientific Leadership: Prof. Renfeng Guo, Chief Scientific Officer, emphasized that izicopan's unique pharmacological profile and favorable metabolic stability provide significant clinical application potential across various inflammatory diseases, potentially offering safer treatment options for patients.
See More
InflaRx to Participate in Biotech Innovation Symposium
- Investor Meeting Schedule: InflaRx N.V. will participate in the Raymond James Biotech Innovation Symposium on April 14, 2026, in New York, planning one-on-one investor meetings to enhance engagement and transparency with investors.
- Innovative Drug Development: InflaRx's lead program, izicopan (INF904), is an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and 2a clinical studies, potentially offering new treatment options for various inflammatory diseases.
- Anti-Inflammatory Therapy Potential: The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated disease-modifying activity and tolerability in multiple clinical studies, indicating its potential in treating inflammatory diseases.
- Global Business Presence: Founded in 2007, InflaRx has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, showcasing its capability for global business expansion and market penetration.
See More
InflaRx Scheduled to Announce FY Earnings Results
- Earnings Announcement Date: InflaRx (IFRX) is set to announce its FY earnings results on March 19 before market open, drawing attention to its performance and future outlook.
- Expected Financial Data: The consensus EPS estimate stands at -$0.17, reflecting a 78.2% year-over-year increase, while the revenue estimate is $0.09 million, indicating a 47.1% year-over-year decline, highlighting challenges the company faces.
- Historical Performance Review: Over the past year, InflaRx has not met EPS estimates 0% of the time and has only met revenue estimates 25% of the time, indicating volatility in profitability and revenue growth.
- Market Reaction: Investors will closely monitor the upcoming earnings report to assess InflaRx's financial health and its competitiveness in the biopharmaceutical sector.
See More
InflaRx Receives Nasdaq Non-Compliance Notice
- Nasdaq Non-Compliance Notice: InflaRx N.V. received a notice from Nasdaq indicating that its stock price has closed below the $1.00 minimum bid requirement for continued listing over the past 30 consecutive business days, potentially impacting the company's financing capabilities.
- Compliance Timeline and Transfer Options: The company has a 180-day period until September 7, 2026, to regain compliance; if unsuccessful, it may apply to transfer its listing to the Nasdaq Capital Market, gaining an additional 180 days, demonstrating the company's strategic response to market regulations.
- Clinical Program Developments: InflaRx's lead program, Izicopan, is under development for inflammatory diseases and has shown therapeutic potential, with plans to discuss future development paths with the FDA, likely in collaboration with a partner, enhancing its competitive position in the market.
- Financial Performance and Stock Volatility: IFRX shares have traded between $0.71 and $1.94 over the past year, closing at $0.94, down 3.56%, reflecting market caution regarding the company's future prospects.
See More
InflaRx Receives Nasdaq Warning for Non-Compliance
- Nasdaq Warning: InflaRx (IFRX) received a compliance warning from Nasdaq after its shares closed below the $1 minimum bid price for 30 consecutive trading days, indicating significant market pressure and potential financial distress for the company.
- Compliance Deadline: The company has been granted a 180-day grace period until September 7, 2026, to regain compliance with the minimum bid price requirement, providing a short-term opportunity for price recovery.
- Potential Transfer: InflaRx indicated it may apply to transfer its listing to the Nasdaq Capital Market, which could grant an additional 180 days until March 8, 2027, to regain compliance, showcasing the company's flexibility in addressing its challenges.
- Stock Price Decline: Following the announcement, InflaRx shares fell by 3.56%, reflecting market concerns about the company's future prospects, which may also impact investor confidence and its ability to raise capital.
See More
InflaRx to Participate in Global Healthcare Conference
- Conference Participation: InflaRx N.V. will participate in the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, with a fireside chat scheduled for March 9 at 9:20 AM, showcasing its latest advancements in anti-inflammatory therapeutics.
- Investor Meetings: On the same day, InflaRx will conduct one-on-one investor meetings aimed at strengthening connections with potential investors and enhancing the company's visibility in the capital markets.
- Technological Innovation: InflaRx focuses on developing anti-inflammatory therapies targeting the complement system, with its lead product izicopan demonstrating promising pharmacokinetic and pharmacodynamic characteristics in clinical studies, indicating potential for treating various inflammatory diseases.
- Company Background: Founded in 2007, InflaRx has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, and is dedicated to developing specific inhibitors of C5a and C5aR to address challenges in multiple inflammatory diseases.
See More
